<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04360343</url>
  </required_header>
  <id_info>
    <org_study_id>LG-SGCL003</org_study_id>
    <nct_id>NCT04360343</nct_id>
  </id_info>
  <brief_title>Compare the Pharmacokinetics, Pharmacodynamics and Safety/Tolerability of LC51-0255 Film-coated Tablet (SG85) With LC51-0255 Uncoated Tablet (SG82) in Healthy Subjects</brief_title>
  <official_title>A Randomized, Open-label, Single Dose, 2-period, 2-sequence, 2-treatment, Crossover Study to Compare the Pharmacokinetics, Pharmacodynamics and Safety/Tolerability of LC51-0255 Film-coated Tablet (SG85) With LC51-0255 Uncoated Tablet (SG82) in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LG Chem</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LG Chem</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the pharmacokinetics, pharmacodynamics and safety/tolerability of LC51-0255
      film-coated tablet (SG85) with LC51-0255 uncoated tablet (SG82) in healthy subjects.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 1, 2020</start_date>
  <completion_date type="Anticipated">March 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetic Outcome Measures</measure>
    <time_frame>baseline,during the procedure</time_frame>
    <description>Peak Plasma Concentration (Cmax)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic Outcome Measures</measure>
    <time_frame>baseline,during the procedure</time_frame>
    <description>Area under the plasma concentration versus time curve (AUC)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">18</enrollment>
  <condition>Ulcerative Colitis</condition>
  <arm_group>
    <arm_group_label>LC51-0255 film-coated tablet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: LC51-0255</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LC51-0255 uncoated tablet</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Drug: LC51-0255</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Film-coated tablet</intervention_name>
    <description>uncoated tablet</description>
    <arm_group_label>LC51-0255 film-coated tablet</arm_group_label>
    <arm_group_label>LC51-0255 uncoated tablet</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy males and females between the age of 19 and 45 at the screening visit

          2. Subjects with the Body Mass Index (BMI) measurement results between 18.0 kg/m2 and
             27.0 kg/m2 at the screening visit

          3. Subjects who were confirmed to be healthy based on the medical history

          4. Subjects who make a voluntary decision to participate in this clinical study and
             provide the informed consent

        Exclusion Criteria:

          1. Subjects with a clinically significant disease or history in liver, kidney,
             gastrointestinal system, respiratory system, musculoskeletal system, endocrine system,
             neuropsychiatric system, hemato-oncology system or cardiovascular system

          2. Subjects with a disease (e.g., Crohn's disease, etc.) or history of surgery (except
             for simple appendectomy and herniotomy) in gastrointestinal system which may affect
             the absorption of the investigational product

          3. Subjects with a history of clinically significant disease or suspicious sign/symptom
             of ophthalmologic disease including uveitis and retinitis at the screening visit

          4. Subjects who had donated whole blood within 2 months, component blood within 1 month,
             or received transfusion within 1 month prior to the first administration day

          5. Subjects who had taken an inducer or inhibitor of drug metabolism such as barbiturates
             etc. within 1 month prior to the first administration day

          6. Subjects who had eaten grapefruit/caffeine-containing food within 3 days prior to the
             first hospitalization or subjects who could not stop taking food containing grapefruit
             or caffeine from 3 days prior to hospitalization to the discharge day

          7. Subjects who had taken any prescription drug or herbal medicine within 2 weeks or any
             over the counter (OTC) drug within 1 week prior to the first administration day
             (however, subjects fulfilling other conditions could participate in the study at the
             investigator's discretion)

          8. Subjects who taking excessive caffeine or alcohol or heavy smoker (caffeine &gt; 5
             units/day, alcohol &gt; 21 units/week (1 unit = 10 mL as pure alcohol), smoking &gt; 10
             cigarettes/day)

          9. Subjects who had a history of tuberculosis (TB) infection or a positive result in the
             Quantiferon TB-Gold test and the chest X-ray in the screening tests

         10. Subjects who unable to take the food provided by the study institution

         11. Subjects who with a positive result in the serology test (hepatitis B test, human
             immunodeficiency virus (HIV) test, hepatitis C test, syphilis test)

         12. Other cases that the investigator consider unsuitable as the subject
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Yujung Lee</last_name>
    <phone>+82 2 6987 4287</phone>
    <email>yujunglee@lgchem.com</email>
  </overall_contact>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 6, 2020</study_first_submitted>
  <study_first_submitted_qc>April 21, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 24, 2020</study_first_posted>
  <last_update_submitted>April 21, 2020</last_update_submitted>
  <last_update_submitted_qc>April 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colitis, Ulcerative</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

